Method of treating insulin resistance, adult onset diabetes and metabolic syndrome x

Abstract

A method of treating insulin resistance, adult onset diabetes, and metabolic syndrome X and its related complications, in mammalian subject is accomplished by intravenously administering to a mammalian subject, a therapeutically effective amount of a liposomal suspension of lipoprotein small unilamellar vesicles (SUVs) comprising predominantly phospholipids. The liposomal suspension is administered over a period of time, whereby in the levels of some or all of blood glucose, insulin, total cholesterol, LDL cholesterol, triglyceride, creatine kinase (CK), creatine kinase-MB (CK-MB), Hb-A1c, lipoprotein (a), SGOT and SGPT fall back within the normal range or are significantly reduced.

Description

FIELD OF THE INVENTION [0001] The present invention relates to a method of treating insulin resistance, adult onset diabetes, and metabolic syndrome X and its related complications in a mammal using a therapeutic liposomal suspension, comprising predominantly phospholipids. BACKGROUND OF THE INVENTION [0002] For maintenance of homeostasis, it is critical to keep a constant supply of glucose to the cells to avoid the occurrence of dysglycemia and its related metabolic imbalances. If left ignored or untreated, metabolic dysglycemia would lead to numerous metabolic diseases, including obesity, heart disease, hypertension, diabetes, chronic fatigue, accelerated aging, degenerative disease, as well as many mental and emotional problems. For this reason, it is important to identify and, at the same time, treat this condition early before costly and disabling degenerative conditions arise that can ruin the quality of life as well as shorten it. [0003] Dysglycemia and diabetes show up very ...

AI Technical Summary

Benefits of technology

[0036] The present invention is based on the discovery that treatment of mammalian subjects with intravenously administered liposomes of the type described herein results in a reduction of insulin resistance and improvement of symptoms of adult onset diabetes, and metabolic syndrome X and its related complications, with negligible or no side effects.

Problems solved by technology

Diabetes or diabetes mellitus is a disease that occurs when the body cannot make use of the glucose in the blood for energy because either the pancreas is not able to make enough insulin or the insulin that is available is not effective.

If the level of insulin is too low for a long period of time, the body begins to break down its stores of fat for energy.

This causes the body to release fatty acids which are then converted into ketone bodies or ketoacids that are toxic at high levels.

Because insulin is not available or is improperly used, the blood sugar level rises above the safety level.

The patient's blood sugar level often rises gradually, taking several years to reach unsafe levels and cause symptoms.

Over time however, insulin production often drops and resistance worsens.

However, the possible adverse effects of insulin on weight gain and the heart are troublesome.

However, when grouped together, they are increasingly atherogenic and enhance the risk of cardiovascular disease (CVD) at any low density lipoprotein cholesterol level.

Overproduction of insulin leads to hypertension.

Increased blood pressure independently increases the risk of atherosclerosis, presumably by promoting the entry of LDL into the subendothelial space, and may exacerbate other metabolic abnormalities.

Although drug therapy has proven to be effective in reducing and treating insulin resistance, adult onset diabetes, and MS-X and its related complications, it leads to side effects, such as weight gain, water retention, slight risk of cardiac events and hypoglycemia, gastrointestinal problems including nausea, flatulence, and diarrhea, lactic acidosis, reduced absorption of vitamin B12 and folic acid, and reduced iron absorption.